Skip to content

Does Aetna cover Zepbound, Wegovy and other GLP-1s?

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Aetna can cover Zepbound and Wegovy, with conditions. Under its non-Medicare pharmacy policy 6450-C, Zepbound pens, Wegovy, Saxenda and Foundayo can be approved with prior authorization. For adult weight loss, the policy asks for a baseline BMI of 35 or more and at least 6 months in a comprehensive weight management program. Other Aetna plans may use a different version or exclude weight-loss drugs.

Key takeaways

  • Under policy 6450-C, adult weight loss needs prior authorization and a baseline BMI of 35 or more.
  • The policy also asks for at least 6 months in a comprehensive weight management program before you start.
  • The policy applies to Zepbound pens. Vials and KwikPens are handled outside it, through LillyDirect.
  • Renewal for Wegovy, Zepbound and Foundayo weight loss needs at least 5 percent loss of baseline body weight.
  • Call the number on your Aetna card and ask whether your plan covers weight-loss medicines and which policy version applies.

What the published policies say

  • Aetna: Foundayo commercial covered with pa

    Aetna's non-Medicare pharmacy policy 6450-C (the BMI 35 version) lists Foundayo and allows it with prior authorization for adult weight loss. The patient needs a baseline BMI of 35 or more and six months in a weight management program. Other Aetna plans may use a different version of the policy or exclude weight-loss drugs.

    • Age 18 or older with a baseline BMI of 35 or more (documentation required)
    • At least 6 months in a comprehensive weight management program before starting the drug
    • Renewal: at least 3 months at a stable maintenance dose and at least 5 percent loss of baseline body weight
    • Initial approval 8 months, then 12 months
    Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term when ALL of the following criteria are met: ... The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.

    Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8

  • Aetna: Saxenda commercial covered with pa

    Aetna's non-Medicare pharmacy policy 6450-C (the BMI 35 version) allows Saxenda with prior authorization for weight loss. Adults need a baseline BMI of 35 or more and six months in a weight management program; there are separate criteria for ages 12 to 17. Other Aetna plans may use a different version of the policy or exclude weight-loss drugs.

    • Adults: age 18 or older with a baseline BMI of 35 or more (documentation required)
    • At least 6 months in a comprehensive weight management program before starting the drug
    • Renewal: at least 16 weeks of therapy and at least 4 percent loss of baseline body weight
    • Initial approval 4 months for adults, then 12 months
    Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term when ALL of the following criteria are met: ... The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.

    Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8

  • Aetna: Wegovy commercial covered with pa

    Aetna's non-Medicare pharmacy policy 6450-C (the BMI 35 version of its weight-loss GLP-1 policy) allows Wegovy with prior authorization. For adult weight loss the patient needs a baseline BMI of 35 or more and six months in a weight management program; separate criteria cover heart-risk reduction (BMI 27 or more with established cardiovascular disease) and MASH. Other Aetna plans may use a different version of the policy or exclude weight-loss drugs.

    • Adult weight loss: age 18 or older with a baseline BMI of 35 or more (documentation required)
    • At least 6 months in a comprehensive weight management program before starting the drug
    • Used with a reduced-calorie diet and increased physical activity
    • Cardiovascular risk reduction: established cardiovascular disease, baseline BMI of 27 or more, no type 2 diabetes
    • Renewal for weight loss: at least 3 months at a stable maintenance dose and at least 5 percent loss of baseline body weight
    • Initial approval 8 months for adult weight loss (injection), then 12 months
    Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term when ALL of the following criteria are met: ... The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.

    Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8

  • Aetna: Zepbound commercial covered with pa

    Aetna's non-Medicare pharmacy policy 6450-C (the BMI 35 version) allows Zepbound pens with prior authorization for adult weight loss at a baseline BMI of 35 or more, and for moderate to severe obstructive sleep apnea in adults with a BMI of 30 or more. The policy says Zepbound vials and KwikPens are handled outside it, through the LillyDirect manufacturer program. Other Aetna plans may use a different version of the policy or exclude weight-loss drugs.

    • Adult weight loss: age 18 or older with a baseline BMI of 35 or more (documentation required)
    • At least 6 months in a comprehensive weight management program before starting the drug
    • Sleep apnea: at least 15 breathing events per hour on a sleep study and a current BMI of 30 or more
    • Renewal for weight loss: at least 3 months at a stable maintenance dose and at least 5 percent loss of baseline body weight
    • Initial approval 8 months for weight loss, 6 months for sleep apnea, then 12 months
    Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term when ALL of the following criteria are met: ... The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.

    Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8

Policies differ between plans from the same insurer and change during the year. Your own plan documents decide.

Aetna publishes more than one version of its weight-loss GLP-1 policy. The one we hold is the “BMI 35” version, numbered 6450-C, from Aetna’s non-Medicare pharmacy policies. Everything below describes that document only. It doesn’t describe Aetna Medicare plans, and your employer’s Aetna plan may run on a different version or leave weight-loss drugs out altogether.

What policy 6450-C says for adult weight loss

The policy covers four medicines in our records: Wegovy, Zepbound, Saxenda and Foundayo. All four need prior authorization (the plan’s approval before it pays), and the adult weight-loss criteria share a core:

  • You’re 18 or older and your baseline BMI (your body mass index before treatment) was 35 or more, with documentation.
  • You took part in a comprehensive weight management program for at least 6 months before starting the drug. The policy describes that as a program encouraging behavioral modification, a reduced-calorie diet and increased physical activity, with continuing follow-up.
  • You use the drug together with a reduced-calorie diet and increased physical activity.

Check the BMI of 35 first. It’s a higher bar than the BMI of 30 that several other payers in our records use, and it’s why this version carries “BMI 35” in its name. If your baseline BMI was below 35, ask Aetna which policy version your plan uses before your prescriber submits anything.

Where the drugs differ

Wegovy has two more doors in this policy. One is cardiovascular risk reduction: established cardiovascular disease, a baseline BMI of 27 or more and no type 2 diabetes. The other is MASH, a liver condition, which has its own criteria.

Zepbound can also be approved for moderate to severe obstructive sleep apnea, with at least 15 breathing events per hour on a sleep study and a current BMI of 30 or more. The policy applies to Zepbound pens. It says vials and KwikPens are handled outside it, through the LillyDirect manufacturer program. So those forms are a self-pay purchase, not a claim on this policy. Our Zepbound cost page lists those prices.

Saxenda has separate criteria for ages 12 to 17, a shorter first approval of 4 months for adults, and its own renewal test.

Foundayo is listed with the adult weight-loss criteria and an 8-month first approval.

Approval lengths and renewal

A first approval for adult weight loss runs 8 months for Wegovy injection, Zepbound and Foundayo. Sleep apnea approvals for Zepbound start at 6 months. After that, approvals run 12 months.

Renewal for weight loss depends on results. For Wegovy, Zepbound and Foundayo, you need at least 3 months at a stable maintenance dose and at least 5 percent loss of baseline body weight. For Saxenda, you need at least 16 weeks of therapy with at least 4 percent loss. The comparison is against your baseline weight, so the number recorded before your first dose matters for every renewal that follows.

What to do next

  1. Call the member number on your Aetna card and ask two things: whether your plan covers weight-loss medicines at all, and which policy version applies.
  2. Gather the paperwork this version asks for: a documented baseline BMI and evidence of the 6 months in a weight management program. The prior authorization checklist shows how to lay it out.
  3. If the request is refused, ask for the denial reason in writing and read our guide to appealing a GLP-1 denial. The appeal letter generator drafts the letter.

If your plan approves the drug, a manufacturer savings card can bring a covered fill down to as little as $25 for Wegovy or $25 for the Zepbound pen, within the card’s caps. If your plan excludes weight-loss drugs, the insurance guide sets out the remaining routes.

Frequently asked questions

Does Aetna cover Wegovy for weight loss?

It can. Aetna's policy 6450-C allows Wegovy with prior authorization for adults with a baseline BMI of 35 or more who have spent at least 6 months in a comprehensive weight management program. The same policy has separate criteria for heart-risk reduction and MASH. Your own Aetna plan may use a different policy version or exclude weight-loss drugs.

Does Aetna cover Zepbound?

Policy 6450-C allows Zepbound pens with prior authorization for adult weight loss at a baseline BMI of 35 or more. It also allows them for moderate to severe obstructive sleep apnea in adults with a BMI of 30 or more. The policy says Zepbound vials and KwikPens are handled outside it, through the LillyDirect manufacturer program.

How long does an Aetna approval for Wegovy or Zepbound last?

In policy 6450-C, the first approval for adult weight loss is 8 months for Wegovy injection, Zepbound and Foundayo, and 4 months for Saxenda in adults. Zepbound for sleep apnea starts with 6 months. Renewals are for 12 months, and for weight loss they depend on documented results.

What does Aetna need to renew a GLP-1 approval?

For Wegovy, Zepbound and Foundayo, policy 6450-C asks for at least 3 months at a stable maintenance dose (the dose you stay on) and at least 5 percent loss of baseline body weight. For Saxenda, it asks for at least 16 weeks of therapy and at least 4 percent loss of baseline body weight. Ask your prescriber's office to record your baseline weight at the start.

Sources (3)

  1. 1.
    Aetna: Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8
    “Authorization may be granted when the requested drug will be used with a reduced-calorie diet AND increased physical activity to reduce excess body weight or maintain weight reduction long term when ALL of the following criteria are met: ... The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy.”
  2. 2.
  3. 3.